Genomic and Proteomic Markers for Recurrent Venous Thromboembolism
Official title: Genomic and Proteomic Determinants of Recurrent Venous Thromboembolism
Funded at University of Washington · NIH-11364727 · Data updated 2026-11-12
Researchers are studying genetic and protein clues to predict who will have another blood clot after an initial VTE event, so doctors can tailor safer, more effective care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 1, 2026 |
| Project end | April 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,608,126 |
| NIH project number | 1R01HL180806-01A1 |
| Project ID | NIH-11364727 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with a history of venous thromboembolism (DVT or PE) who are under consideration for ongoing or future anticoagulation decisions.
✕Less likely to help
Patients without a history of VTE or those not involved in anticoagulation management may not benefit directly.
What this research studies
If you’ve had a first venous clot, this project looks for genetic and protein factors that might signal higher risk of a second clot in people like you. The study uses patient data and samples collected over time to identify markers associated with recurrence, with the aim of improving risk prediction beyond current methods. The findings could lead to better personalized treatment decisions and safer anticoagulation strategies. Participation would be through existing patient cohorts and collaboration with the University of Washington, focusing on people with a history of VTE.
Why it matters
Potential benefit: If successful, the research could improve predictions of who is at risk for recurrence and guide safer, more effective anticoagulant choices.
How similar studies have gone: Prior work suggests genomic and proteomic factors influence VTE recurrence, with ongoing research building on these approaches, making this a promising but still exploratory area.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Smith, Nicholas L — University of Washington
- Study coordinator: Smith, Nicholas L
Related research
Other NIH-funded projects on the same topics.
-
Statins to Prevent Cancer-Associated Blood Clots in Cancer Patients
A large study will test whether taking rosuvastatin every day for a year can lower the chance of dangerous blood clots in people with cancer, without raising the risk of bleeding.
-
Optimal use of blood thinners for venous clots in people with cirrhosis
This grant hopes to figure out the safest and most effective way to use oral anticoagulants for adults with cirrhosis who develop venous clots.
-
PET/CT imaging to detect chemotherapy-related vascular harm in young cancer patients
A non-invasive PET/CT scan method using standard care imaging is being tested to identify which pediatric and young adult cancer patients are at higher risk of blood clots from chemotherapy.
-
Statins to Prevent Cancer-Associated Blood Clots in Cancer Patients
A large clinical trial will test whether taking rosuvastatin daily for a year helps prevent dangerous blood clots in people with newly diagnosed or relapsed cancer who aren’t already getting anticoagulants.
-
BCOR's role in blood clot risk and liver genetics
A Johns Hopkins-led study is exploring how a human gene, BCOR, may control liver-produced clotting factors to influence venous blood clots.
-
Personalized risk-prediction for hospital-acquired blood clots in adults
A real-time risk model helps doctors identify adults in the hospital who are at higher risk of developing blood clots so they can prevent them safely.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.